Diabetic gastroparesis: Recent insights into pathophysiology and implications for management

Expert Review of Gastroenterology and Hepatology

Volumn 7, Issue 2, 2013, Pages 127-139

  Thazhath, Sony S ^a   Jones, Karen L ^a   Horowitz, Michael ^a   Rayner, Christopher K ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

diabetic gastroparesis; heme oxygenase 1; interstitial cells of Cajal; neuronal nitric oxide synthase; postprandial glycemia; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ACOTIAMIDE; AMITRIPTYLINE; BOTULINUM TOXIN; CARBON MONOXIDE; CISAPRIDE; CLEBOPRIDE; DOMPERIDONE; DRONABINOL; ERYTHROMYCIN; EXENDIN 4; HEMIN; KETAMINE; LIRAGLUTIDE; METOCLOPRAMIDE; MITEMCINAL; MOSAPRIDE; NARONAPRIDE; NORTRIPTYLINE; ONDANSETRON; ORAL ANTIDIABETIC AGENT; PRAMLINTIDE; PROKINETIC AGENT; PROMETHAZINE; PRUCALOPRIDE; RENZAPRIDE; SILDENAFIL; TEGASEROD; ULIMORELIN; UNINDEXED DRUG; VELUSETRAG;

ABDOMINAL PAIN; ACUPRESSURE; ACUPUNCTURE; BREATH ANALYSIS; CENTRAL NERVOUS SYSTEM DISEASE; DIABETES MELLITUS; DIAGNOSTIC EQUIPMENT; DIET THERAPY; DISEASE SEVERITY; DRUG EFFECT; DRUG FATALITY; DRUG SAFETY; ECHOGRAPHY; ELECTROACUPUNCTURE; ELECTROGASTROGRAPHY; ELECTROSTIMULATION THERAPY; ENZYME ACTIVATION; GASTRECTOMY; GLYCEMIC CONTROL; HEART DISEASE; HUMAN; HYPERGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INTERSTITIAL CELL OF CAJAL; LOW DRUG DOSE; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; REVIEW; STEM CELL TRANSPLANTATION; STOMACH EMPTYING; STOMACH MOTILITY; STOMACH PARESIS; STOMACH SCINTISCANNING; TARDIVE DYSKINESIA; TRANSCRANIAL MAGNETIC STIMULATION; WIRELESS MOTILITY CAPSULE;

ANTIEMETICS; BOTULINUM TOXINS; COMPLEMENTARY THERAPIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ELECTRIC STIMULATION THERAPY; GASTRIC EMPTYING; GASTROINTESTINAL MOTILITY; GASTROPARESIS; HUMANS; MAGNETIC RESONANCE IMAGING; MUSCLE CONTRACTION; NEURAL STEM CELLS; NEUROMUSCULAR AGENTS; NUTRITIONAL STATUS; PAIN MANAGEMENT; PROGNOSIS;

EID: 84873134743     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.12.82     Document Type: Review

References (132)

1. Boas I. Diseases of the Stomach (9th Edition). Leipzig, Germany, 200 (1925).
2. Kassander P. Asymptomatic gastric retention in diabetics (gastroparesis diabeticorum). Ann. Intern. Med. 48(4), 797-812 (1958).
3. Parkman HP, Camilleri M, Farrugia G et al. Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting. Neurogastroenterol. Motil. 22(2), 113-133 (2010).
4. Khoo J, Rayner CK, Jones KL, Horowitz M. Pathophysiology and management of gastroparesis. Expert Rev. Gastroenterol. Hepatol. 3(2), 167-181 (2009).
5. Samsom M, Vermeijden JR, Smout AJ et al. Prevalence of delayed gastric emptying in diabetic patients and relationship to dyspeptic symptoms: a prospective study in unselected diabetic patients. Diabetes Care 26(11), 3116-3122 (2003). (Pubitemid 37339507)
6. Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care 24(7), 1264-1269 (2001). (Pubitemid 33716409)
7. Choung RS, Locke GR 3rd, Schleck CD, Zinsmeister AR, Melton LJ 3rd, Talley NJ. Risk of gastroparesis in subjects with Type 1 and 2 diabetes in the general population. Am. J. Gastroenterol. 107(1), 82-88 (2012).
8. Camilleri M, Bharucha AE, Farrugia G. Epidemiology, mechanisms, and management of diabetic gastroparesis. Clin. Gastroenterol. Hepatol. 9(1), 5-12; quiz e7 (2011).
9. Wang YR, Fisher RS, Parkman HP. Gastroparesis-related hospitalizations in the United States: trends, characteristics, and outcomes, 1995-2004. Am. J. Gastroenterol. 103, 313-322 (2008). (Pubitemid 351248745)
10. O'Grady G, Du P, Cheng LK et al. Origin and propagation of human gastric slow-wave activity defined by high-resolution mapping. Am. J. Physiol. Gastrointest. Liver Physiol. 299(3), G585-G592 (2010).
11. Chang J, Rayner CK, Jones KL, Horowitz M. Diabetic gastroparesis - backwards and forwards. J. Gastroenterol. Hepatol. 26(Suppl. 1), 46-57 (2011).
12. Kashyap P, Farrugia G. Diabetic gastroparesis: what we have learned and had to unlearn in the past 5 years. Gut 59(12), 1716-1726 (2010).
13. Jones K, Edelbroek M, Horowitz M et al. Evaluation of antral motility in humans using manometry and scintigraphy. Gut 37(5), 643-648 (1995).
14. Samsom M, Roelofs JM, Akkermans LM, van Berge Henegouwen GP, Smout AJ. Proximal gastric motor activity in response to a liquid meal in Type I diabetes mellitus with autonomic neuropathy. Dig. Dis. Sci. 43(3), 491-496 (1998). (Pubitemid 28155568)
15. Samsom M, Jebbink RJ, Akkermans LM, van Berge-Henegouwen GP, Smout AJ. Abnormalities of antroduodenal motility in Type I diabetes. Diabetes Care 19(1), 21-27 (1996). (Pubitemid 26006609)
16. Mearin F, Camilleri M, Malagelada Jr. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 90(6), 1919-1925 (1986). (Pubitemid 16085599)
17. Fraser RJ, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. Hyperglycaemia slows gastric emptying in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 33(11), 675-680 (1990). (Pubitemid 20377931)
18. Horowitz M, Harding PE, Maddox A et al. Gastric and oesophageal emptying in insulin-dependent diabetes mellitus. J. Gastroenterol. Hepatol. 1, 97-113 (1986).
19. Koch KL, Stern RM, Stewart WR, Vasey MW. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment. Am. J. Gastroenterol. 84(9), 1069-1075 (1989). (Pubitemid 19237995)
20. Horowitz M, Maddox AF, Wishart JM, Harding PE, Chatterton BE, Shearman DJ. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur. J. Nucl. Med. 18(4), 229-234 (1991).
21. Pasricha PJ, Pehlivanov ND, Gomez G, Vittal H, Lurken MS, Farrugia G. Changes in the gastric enteric nervous system and muscle: a case report on two patients with diabetic gastroparesis. BMC Gastroenterol. 8, 21 (2008).
22. Grover M, Farrugia G, Lurken MS et al.; NIDDK Gastroparesis Clinical Research Consortium. Cellular changes in diabetic and idiopathic gastroparesis. Gastroenterology 140(5), 1575-1585.e8 (2011).
23. Grover M, Bernard CE, Pasricha PJ et al. Clinical-histological associations in gastroparesis: results from the Gastroparesis Clinical Research Consortium. Neurogastroenterol. Motil. 24(6), 531-539 (2012).
24. Gangula PR, Maner WL, Micci MA, Garfield RE, Pasricha PJ. Diabetes induces sex-dependent changes in neuronal nitric oxide synthase dimerization and function in the rat gastric antrum. Am. J. Physiol. Gastrointest. Liver Physiol. 292(3), G725-G733 (2007). (Pubitemid 46440386)
25. Desai KM, Sessa WC, Vane Jr. Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature 351(6326), 477-479 (1991). (Pubitemid 21896622)
26. Orihata M, Sarna SK. Nitric oxide mediates mechano- and chemo-receptoractivated intestinal feedback control of gastric emptying. Dig. Dis. Sci. 41(7), 1303-1309 (1996). (Pubitemid 26245907)
27. Sun WM, Doran S, Jones KL et al. Effects of nitroglycerin on liquid gastric emptying and antropyloroduodenal motility. Am. J. Physiol. 275(5 Pt 1), G1173-G1178 (1998).
28. Dishy V, Cohen Pour M, Feldman L et al. The effect of sildenafil on gastric emptying in patients with end-stage renal failure and symptoms of gastroparesis. Clin. Pharmacol. Ther. 76(3), 281-286 (2004). (Pubitemid 39221801)
29. Ordög T, Takayama I, Cheung WK, Ward SM, Sanders KM. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. Diabetes 49(10), 1731-1739 (2000).
30. Horváth VJ, Vittal H, Lörincz A et al. Reduced stem cell factor links smooth myopathy and loss of interstitial cells of cajal in murine diabetic gastroparesis. Gastroenterology 130(3), 759-770 (2006). (Pubitemid 43374526)
31. Iwasaki H, Kajimura M, Osawa S et al. A deficiency of gastric interstitial cells of Cajal accompanied by decreased expression of neuronal nitric oxide synthase and substance P in patients with Type 2 diabetes mellitus. J. Gastroenterol. 41(11), 1076-1087 (2006). (Pubitemid 44896722)
32. Forster J, Damjanov I, Lin Z, Sarosiek I, Wetzel P, McCallum RW. Absence of the interstitial cells of Cajal in patients with gastroparesis and correlation with clinical findings. J. Gastrointest. Surg. 9(1), 102-108 (2005). (Pubitemid 40037877)
33. Faussone-Pellegrini MS, Grover M, Pasricha PJ et al.; NIDDK Gastroparesis Clinical Research Consortium (GpCRC). Ultrastructural differences between diabetic and idiopathic gastroparesis. J. Cell. Mol. Med. 16(7), 1573-1581 (2012).
34. Ordög T. Interstitial cells of Cajal in diabetic gastroenteropathy. Neurogastroenterol. Motil. 20(1), 8-18 (2008). (Pubitemid 350277445)
35. Nishikawa T, Edelstein D, Du XL et al. Normalizing mitochondrial superoxideproduction blocks three pathways of hyperglycaemic damage. Nature 404(6779), 787-790 (2000). (Pubitemid 30212409)
36. Watkins CC, Sawa A, Jaffrey S et al. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J. Clin. Invest. 106(3), 373-384 (2000). (Pubitemid 30655637)
37. Cellek S. Point of NO return for nitrergic nerves in diabetes: a new insight into diabetic complications. Curr. Pharm. Des. 10(29), 3683-3695 (2004). (Pubitemid 39386583)
38. Choi KM, Gibbons SJ, Nguyen TV et al. Heme oxygenase-1 protects interstitial cells of Cajal from oxidative stress and reverses diabetic gastroparesis. Gastroenterology 135(6), 2055-64, 2064.e1 (2008).
39. Kashyap PC, Choi KM, Dutta N et al. Carbon monoxide reverses diabetic gastroparesis in NOD mice. Am. J. Physiol. Gastrointest. Liver Physiol. 298(6), G1013-G1019 (2010).
40. Bharucha AE, Kulkarni A, Choi KM et al. First-in-human study demonstrating pharmacological activation of heme oxygenase-1 in humans. Clin. Pharmacol. Ther. 87(2), 187-190 (2010).
41. Stacher G, Schernthaner G, Francesconi M et al. Cisapride versus placebo for 8 weeks on glycemic control and gastric emptying in insulin-dependent diabetes: a double blind cross-over trial. J. Clin. Endocrinol. Metab. 84(7), 2357-2362 (1999).
42. Abell TL, Camilleri M, Donohoe K et al.; American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. J. Nucl. Med. Technol. 36(1), 44-54 (2008). (Pubitemid 351520592)
43. Chew CG, Bartholomeusz FD, Bellon M, Chatterton BE. Simultaneous 13C/14C dual isotope breath test measurement of gastric emptying of solid and liquid in normal subjects and patients: comparison with scintigraphy. Nucl. Med. Rev. Cent. East. Eur. 6(1), 29-33 (2003). (Pubitemid 36722585)
44. Sanaka M, Urita Y, Sugimoto M, Yamamoto T, Kuyama Y. Comparison between gastric scintigraphy and the [13C]-acetate breath test with Wagner-Nelson analysis in humans. Clin. Exp. Pharmacol. Physiol. 33(12), 1239-1243 (2006). (Pubitemid 44923914)
45. Saad RJ, Hasler WL. A technical review and clinical assessment of the wireless motility capsule. Gastroenterol. Hepatol. 7(12), 795-804 (2011).
46. Kuo B, McCallum RW, Koch KL et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labelled meal in healthy and gastroparetic subjects. Aliment. Pharmacol. Ther. 27(2), 186-196 (2008). (Pubitemid 350256610)
47. Gilja OH, Hausken T, degaard S, Berstad A. Gastric emptying measured by ultrasonography. World J. Gastroenterol. 5(2), 93-94 (1999).
48. Gentilcore D, Hausken T, Horowitz M, Jones KL. Measurements of gastric emptying of low- and high-nutrient liquids using 3D ultrasonography and scintigraphy in healthy subjects. Neurogastroenterol. Motil. 18(12), 1062-1068 (2006). (Pubitemid 44748270)
49. Rao SS, Camilleri M, Hasler WL et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. Neurogastroenterol. Motil. 23(1), 8-23 (2011).
50. Du P, O'Grady G, Cheng LK, Pullan AJ. A multiscale model of the electrophysiological basis of the human electrogastrogram. Biophys. J. 99(9), 2784-2792 (2010).
51. Lin Z, Sarosiek I, Forster J, Damjanov I, Hou Q, McCallum RW. Association of the status of interstitial cells of Cajal and electrogastrogram parameters, gastric emptying and symptoms in patients with gastroparesis. Neurogastroenterol. Motil. 22(1), 56-61, e10 (2010).
52. Jones KL, Horowitz M, Wishart MJ, Maddox AF, Harding PE, Chatterton BE. Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus. J. Nucl. Med. 36(12), 2220-2228 (1995).
53. Revicki DA, Rentz AM, Dubois D et al. Development and validation of a patientassessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Aliment. Pharmacol. Ther. 18(1), 141-150 (2003). (Pubitemid 36897991)
54. Revicki DA, Camilleri M, Kuo B, Szarka LA, McCormack J, Parkman HP. Evaluating symptom outcomes in gastroparesis clinical trials: validity and responsiveness of the Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD). Neurogastroenterol. Motil. 24(5), 456-63, e215 (2012).
55. Reddymasu SC, McCallum RW. Small intestinal bacterial overgrowth in gastroparesis: are there any predictors? J. Clin. Gastroenterol. 44(1), e8-e13 (2010).
56. Hebbard GS, Sun WM, Bochner F, Horowitz M. Pharmacokinetic considerations in gastrointestinal motor disorders. Clin. Pharmacokinet. 28(1), 41-66 (1995).
57. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of Type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26(3), 881-885 (2003). (Pubitemid 36929359)
58. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 36(9), 857-862 (1993). (Pubitemid 23248159)
59. Jones KL, Horowitz M, Carney BI, Wishart JM, Guha S, Green L. Gastric emptying in early noninsulin-dependent diabetes mellitus. J. Nucl. Med. 37(10), 1643-1648 (1996). (Pubitemid 26337168)
60. Nowak TV, Johnson CP, Kalbfleisch JH et al. Highly variable gastric emptying in patients with insulin dependent diabetes mellitus. Gut 37(1), 23-29 (1995).
61. Gonlachanvit S, Hsu CW, Boden GH et al. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in Type-II diabetic patients. Dig. Dis. Sci. 48(3), 488-497 (2003). (Pubitemid 36324155)
62. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 63(2), 492-498 (1986). (Pubitemid 16035703)
63. Little TJ, Pilichiewicz AN, Russo A et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J. Clin. Endocrinol. Metab. 91(5), 1916-1923 (2006).
64. Deane AM, Nguyen NQ, Stevens JE et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J. Clin. Endocrinol. Metab. 95(1), 215-221 (2010).
65. Nauck MA, Niedereichholz U, Ettler R et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 273(5 Pt 1), E981-E988 (1997).
66. Baruah MP, Kalra S. The novel use of GLP-1 analogue and insulin combination in Type 2 diabetes mellitus. Recent Pat. Endocr. Metab. Immune Drug Discov. 6(2), 129-135 (2012).
67. Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen LB. Liraglutide: short-lived effect on gastric emptying - long lasting effects on body weight. Diabetes. Obes. Metab. 14(6), 531-538 (2012).
68. Drucker DJ, Buse JB, Taylor K et al.; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of Type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372(9645), 1240-1250 (2008).
69. Linnebjerg H, Park S, Kothare PA et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in Type 2 diabetes. Regul. Pept. 151(1-3), 123-129 (2008).
70. Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am. J. Physiol. Gastrointest. Liver Physiol. 278(6), G946-G951 (2000). (Pubitemid 30439174)
71. Ishii M, Nakamura T, Kasai F, Onuma T, Baba T, Takebe K. Altered postprandial insulin requirement in IDDM patients with gastroparesis. Diabetes Care 17(8), 901-903 (1994). (Pubitemid 24235516)
72. Horowitz M, Jones KL, Rayner CK, Read NW. 'Gastric' hypoglycaemia - an important concept in diabetes management. Neurogastroenterol. Motil. 18(6), 405-407 (2006). (Pubitemid 43742553)
73. Sharma D, Morrison G, Joseph F, Purewal TS, Weston PJ. The role of continuous subcutaneous insulin infusion therapy in patients with diabetic gastroparesis. Diabetologia 54(11), 2768-2770 (2011).
74. Navarro X, Sutherland DE, Kennedy WR. Long-term effects of pancreatic transplantation on diabetic neuropathy. Ann. Neurol. 42(5), 727-736 (1997). (Pubitemid 27481545)
75. Hathaway DK, Abell T, Cardoso S, Hartwig MS, el Gebely S, Gaber AO. Improvement in autonomic and gastric function following pancreas-kidney versus kidney-alone transplantation and the correlation with quality of life. Transplantation 57(6), 816-822 (1994). (Pubitemid 24114670)
76. Olausson EA, Alpsten M, Larsson A, Mattsson H, Andersson H, Attvall S. Small particle size of a solid meal increases gastric emptying and late postprandial glycaemic response in diabetic subjects with gastroparesis. Diabetes Res. Clin. Pract. 80(2), 231-237 (2008).
77. Lipp RW, Schnedl WJ, Hammer HF, Kotanko P, Leb G, Krejs GJ. Effects of postprandial walking on delayed gastric emptying and intragastric meal distribution in longstanding diabetics. Am. J. Gastroenterol. 95(2), 419-424 (2000). (Pubitemid 30106170)
78. Appadu BL, Mushambi MC, Allott J, Hampton H, Rowbotham DJ. The effect of posture on gastric emptying. Int. J. Obstet. Anesth. 4, 67 (1995).
79. Sturm A, Holtmann G, Goebell H, Gerken G. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 60(5), 422-427 (1999). (Pubitemid 29401770)
80. Tack J, Camilleri M, Chang L et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment. Pharmacol. Ther. 35(7), 745-767 (2012).
81. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am. J. Gastroenterol. 88(2), 203-207 (1993). (Pubitemid 23053470)
82. Jones KL, Berry M, Kong MF, Kwiatek MA, Samsom M, Horowitz M. Hyperglycemia attenuates the gastrokinetic effect of erythromycin and affects the perception of postprandial hunger in normal subjects. Diabetes Care 22(2), 339-344 (1999). (Pubitemid 29056932)
83. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N. Engl. J. Med. 366(20), 1881-1890 (2012).
84. McCallum RW, Cynshi O; US INVESTIGATIVE TEAM. Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multicenter, placebo-controlled trial. Aliment. Pharmacol. Ther. 26(1), 107-116 (2007). (Pubitemid 46889836)
85. Sanger GJ, Westaway SM, Barnes AA et al. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol. Motil. 21(6), 657-664, e30 (2009).
86. Takahashi N, Koba N, Yamamoto T, Sudo M. Characterisation of a novel potent and selective small molecule motilin receptor agonist, RQ-00201894. Gastroenterology 138, Abstract W1390 (2010).
87. Suzuki H, Matsuzaki J, Hibi T. Ghrelin and oxidative stress in gastrointestinal tract. J. Clin. Biochem. Nutr. 48(2), 122-125 (2011).
88. Murray CD, Martin NM, Patterson M et al. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study. Gut 54(12), 1693-1698 (2005). (Pubitemid 41697666)
89. Tack J, Depoortere I, Bisschops R, Verbeke K, Janssens J, Peeters T. Influence of ghrelin on gastric emptying and mealrelated symptoms in idiopathic gastroparesis. Aliment. Pharmacol. Ther. 22(9), 847-853 (2005). (Pubitemid 41568544)
90. Ang D, Nicolai H, Vos R et al. Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man. Neurogastroenterol. Motil. 21(5), 528-533, e8 (2009).
91. Greenwood-Van Meerveld B, Kriegsman M, Nelson R. Ghrelin as a target for gastrointestinal motility disorders. Peptides 32(11), 2352-2356 (2011).
92. Shin A, Camilleri M, Busciglio I et al. Randomized controlled Phase Ib study of ghrelin agonist, RM-131, in Type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care 36(1), 41-48 (2013).
93. Fraser GL, Hoveyda HR, Tannenbaum GS. Pharmacological demarcation of the growth hormone, gut motility and feeding effects of ghrelin using a novel ghrelin receptor agonist. Endocrinology 149(12), 6280-6288 (2008).
94. Charoenthongtrakul S, Giuliana D, Longo KA et al. Enhanced gastrointestinal motility with orally active ghrelin receptor agonists. J. Pharmacol. Exp. Ther. 329(3), 1178-1186 (2009).
95. Ejskjaer N, Dimcevski G, Wo J et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol. Motil. 22(10), 1069-e281 (2010).
96. Ejskjaer N, Vestergaard ET, Hellström PM et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment. Pharmacol. Ther. 29(11), 1179-1187 (2009).
97. Seto K, Sasaki T, Katsunuma K, Kobayashi N, Tanaka K, Tack J. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol. Motil. 20(9), 1051-1059 (2008).
98. Hasler WL. Gastroparesis: pathogenesis, diagnosis and management. Nat. Rev. Gastroenterol. Hepatol. 8(8), 438-453 (2011).
99. Sawhney MS, Prakash C, Lustman PJ, Clouse RE. Tricyclic antidepressants forchronic vomiting in diabetic patients. Dig. Dis. Sci. 52(2), 418-424 (2007). (Pubitemid 46202816)
100. Kim SW, Shin IS, Kim JM et al. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics 47(5), 440-442 (2006).
101. Hoogerwerf WA, Pasricha PJ, Kalloo AN, Schuster MM. Pain: the overlooked symptom in gastroparesis. Am. J. Gastroenterol. 94(4), 1029-1033 (1999). (Pubitemid 29173623)
102. Lahr C, Halley L, Adams K, Spree D, Subramony C, Abell T. 317 Histology reveals neuropathy likely source of abdominal pain in gastroparesis. Eur. J. Pain Suppl. 4, 91 (2010).
103. Cherian D, Sachdeva P, Fisher RS, Parkman HP. Abdominal pain is a frequent symptom of gastroparesis. Clin. Gastroenterol. Hepatol. 8(8), 676-681 (2010).
104. Camilleri M. Novel pharmacology: asimadoline, a κ-opioid agonist, and visceral sensation. Neurogastroenterol. Motil. 20(9), 971-979 (2008).
105. Wu DJ, Dib C, Hoelzer B, McMahon M, Mueller P. Coeliac plexus block in the management of chronic abdominal pain due to severe diabetic gastroparesis. BMJ Case Rep. doi:10.1136/bcr.06.2009.1986 (2009) (Epub ahead of print).
106. Chiarioni G, Whitehead WE. The role of biofeedback in the treatment of gastrointestinal disorders. Nat. Clin. Pract. Gastroenterol. Hepatol. 5(7), 371-382 (2008). (Pubitemid 351984293)
107. Thomas MP, Wilson CH, Nayar M et al. Endoscopic botulinum toxin injection for the treatment of diabetic gastropathy in pancreas and islet-cell transplant patients. Exp. Clin. Transplant. 10(2), 168-171 (2012).
108. Ezzeddine D, Jit R, Katz N, Gopalswamy N, Bhutani MS. Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest. Endosc. 55(7), 920-923 (2002). (Pubitemid 41127918)
109. Gupta P, Rao SS. Attenuation of isolated pyloric pressure waves in gastroparesis in response to botulinum toxin injection: a case report. Gastrointest. Endosc. 56(5), 770-772 (2002). (Pubitemid 36531726)
110. Lacy BE, Crowell MD, Schettler-Duncan A, Mathis C, Pasricha PJ. The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus. Diabetes Care 27(10), 2341-2347 (2004). (Pubitemid 39281383)
111. Ben-Youssef R, Baron PW, Franco E, Walter MH, Lewis T, Ojogho O. Intrapyloric injection of botulinum toxin a for the treatment of persistent gastroparesis following successful pancreas transplantation. Am. J. Transplant. 6(1), 214-218 (2006). (Pubitemid 43382222)
112. Arts J, Holvoet L, Caenepeel P et al. Clinical trial: a randomized-controlled crossover study of intrapyloric injection of botulinum toxin in gastroparesis. Aliment. Pharmacol. Ther. 26(9), 1251-1258 (2007). (Pubitemid 47620416)
113. Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am. J. Gastroenterol. 103(2), 416-423 (2008). (Pubitemid 351248749)
114. McCallum RW, Dusing RW, Sarosiek I, Cocjin J, Forster J, Lin Z. Mechanisms of symptomatic improvement after gastric electrical stimulation in gastroparetic patients. Neurogastroenterol. Motil. 22(2), 161-167, e50 (2010).
115. O'Grady G, Egbuji JU, Du P, Cheng LK, Pullan AJ, Windsor JA. High-frequency gastric electrical stimulation for the treatment of gastroparesis: a meta-analysis. World J. Surg. 33(8), 1693-1701 (2009).
116. Maranki JL, Lytes V, Meilahn JE et al. Predictive factors for clinical improvement with Enterra gastric electric stimulation treatment for refractory gastroparesis. Dig. Dis. Sci. 53(8), 2072-2078 (2008).
117. McCallum RW, Snape W, Brody F, Wo J, Parkman HP, Nowak T. Gastric electrical stimulation with Enterra therapy improves symptoms from diabetic gastroparesis in a prospective study. Clin. Gastroenterol. Hepatol. 8(11), 947-54; quiz e116 (2010).
118. Chen JD, Xu X, Zhang J et al. Efficiency and efficacy of multi-channel gastric electrical stimulation. Neurogastroenterol. Motil. 17(6), 878-882 (2005). (Pubitemid 41746526)
119. Song GQ, Hou X, Yang B, Sun Y, Qian W, Chen JD. A novel method of 2-channel dual-pulse gastric electrical stimulation improves solid gastric emptying in dogs. Surgery 143(1), 72-78 (2008). (Pubitemid 350266029)
120. Watkins PJ, Buxton-Thomas MS, Howard ER. Long-term outcome after gastrectomy for intractable diabetic gastroparesis. Diabet. Med. 20(1), 58-63 (2003). (Pubitemid 36098866)
121. Van Sickle KR, McClusky DA, Swafford VA, Smith CD. Delayed gastric emptying in patients undergoing antireflux surgery: analysis of a treatment algorithm. J. Laparoendosc. Adv. Surg. Tech. A 17(1), 7-11 (2007). (Pubitemid 46466658)
122. Hibbard ML, Dunst CM, Swanström LL. Laparoscopic and endoscopic pyloroplasty for gastroparesis results in sustained symptom improvement. J. Gastrointest. Surg. 15(9), 1513-1519 (2011).
123. Micci MA, Kahrig KM, Simmons RS, Sarna SK, Espejo-Navarro MR, Pasricha PJ. Neural stem cell transplantation in the stomach rescues gastric function in neuronal nitric oxide synthase-deficient mice. Gastroenterology 129(6), 1817-1824 (2005). (Pubitemid 41772960)
124. Hasler WL, Parkman HP, Wilson LA et al.; NIDDK Gastroparesis Clinical Research Consortium. Psychological dysfunction is associated with symptom severity but not disease etiology or degree of gastric retention in patients with gastroparesis. Am. J. Gastroenterol. 105(11), 2357-2367 (2010).
125. Lustman PJ, Anderson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 23(7), 934-942 (2000). (Pubitemid 30480020)
126. d'Emden H, Holden L, McDermott B et al. Concurrent validity of self-report measures of eating disorders in adolescents with Type 1 diabetes. Acta Paediatr. 101(9), 973-978 (2012).
127. Ouyang H, Yin J, Wang Z, Pasricha PJ, Chen JD. Electroacupuncture accelerates gastric emptying in association with changes in vagal activity. Am. J. Physiol. Gastrointest. Liver Physiol. 282(2), G390-G396 (2002). (Pubitemid 34651697)
128. Rashed H, Cutts T, Abell T et al. Predictors of response to a behavioral treatment in patients with chronic gastric motility disorders. Dig. Dis. Sci. 47(5), 1020-1026 (2002). (Pubitemid 34439178)
129. Hyett B, Martinez FJ, Gill BM et al. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology 137(2), 445-452 (2009).
130. Kong MF, Horowitz M, Jones KL, Wishart JM, Harding PE. Natural history of diabetic gastroparesis. Diabetes Care 22(3), 503-507 (1999). (Pubitemid 29106912)
131. Jones KL, Russo A, Berry MK, Stevens JE, Wishart JM, Horowitz M. A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus. Am. J. Med. 113(6), 449-455 (2002). (Pubitemid 35335795)
132. Hejazi RA, Sarosiek I, Roeser K, McCallum RW. Does grading the severity of gastroparesis based on scintigraphic gastric emptying predict the treatment outcome of patients with gastroparesis? Dig. Dis. Sci. 56(4), 1147-1153 (2011).